References
- Abicht A, Muller JS, Lochmuller H. Congenital myasthenic syndromes. 2003 May 9 [updated 2016 jul14]. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LHJ, Mefford HC, Stephens K, Amemiya A, Ledbetter N, editors. GeneReviews. Seattle (WA): University of Washington; 1993–2017.
- Vanhaesebrouck AE, Beeson D. The congenital myasthenic syndromes expanding genetic and phenotypic spectrums and refgies. Curr Opin Neurol. 2019;32(5):696–703.
- Freed D, et al. The Sentieon Genomics Tools -A fast and accurate solution to variant calling from next- generation sequence data. BioRxiv. 2017:115717.
- McLaren W, Pritchard B, Rios D, et al. Deriving the consequences of genomic variants with the ensembl API and SNP effect predictor. Bioinformatics. 2010;26(16):2069–2070.
- Zebrino DR, et al. Ensembl 2018. Nucl Acids Res. 2018;46(D1):D754–D761.
- Rodríguez Cruz PM, Palace J, Ramjattan H, et al. Salbutamol and ephedrine in the treatment of severe achr deficiency syndromes. Neurology. 2015;85(12):1043–1047.
- Chang T, Cossins J, Beeson D. A rare c.183_187dupCTCAC mutation of the acetylcholine receptor CHRNE gene in a South Asian female with congenital myasthenic syndrome: a case report. BMC Neurol. 2016;16(1):195.
- Chaouch A, Müller JS, Guergueltcheva V, et al. A retrospective clinical study of the treatment of slow-channel congenital myasthenic syndrome. J Neurol. 2012;259(3):474–481.
- Ardissone A, Moroni I, Bernasconi P, et al. Congenital myasthenic syndrome: phenotypic variability in patients harbouring p.T159P mutation in CHRNE gene. Acta Myol. 2017;36(1):28–32.
- Beeson D. Congenital myasthenic syndromes: recent advances. Curr Opin Neurol. 2016; Oct29(5):565–571.
- Cho A, Kim SY, Lee JS, et al. Wide heterogenecity of congenital myasthenic syndromes. J Genet Med. 2020;17(2):73–78.
- Webster RG, Vanhaesebrouck AE, Maxwell SE, et al. Effect of salbutamol on neuromuscular junction and structure in a mouse model of DOK7 congenital myasthenia. Hum Mol Genet. 2020;29(14):2325–2336.